Phase I study of the safety and persistence of 0.1% UC-781 vaginal gel in HIV-1 seronegative women

Trial Profile

Phase I study of the safety and persistence of 0.1% UC-781 vaginal gel in HIV-1 seronegative women

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2012

At a glance

  • Drugs UC 781 (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 10 Apr 2012 Results published in the Journal of acquired immune deficiency syndromes (1999).
    • 03 Mar 2009 Status changed from recruiting to completed, as reported by ClincialTrials.gov.
    • 25 Sep 2008 Planned end date changed to 1 Apr 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top